Organon signs agreements in Ireland and Brazil:
This article was originally published in Clinica
Organon Teknika is to distribute Epitope's OraQuick oral fluid rapid test for HIV in Ireland and also Visible Genetics' OpenGene and GeneKits in Brazil. The Irish agreement calls for Organon to collaborate on the final product development and manufacture pre-production lots. The Brazilian deal is a four-year agreement guaranteeing Visible Genetics a minimum annual revenue. The companies say that the deal will open the Latin American market to drug resistance testing.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.